Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
Plasma homovanillic acid (HVA), but not plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), was substantially increased in 4 patients undergoing hemodialysis, 3 patients with chronic renal failure, and 3 patients receiving carbidopa/levodopa for Parkinson's disease. These conditions should be considered in psychiatric research involving plasma HVA.
Bowers
M B
MB
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA.
D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000097:blood / Q000150:complications; D005260:Female; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D001523:Mental Disorders / Q000097:blood / Q000150:complications*; D008734:Methoxyhydroxyphenylglycol / Q000097:blood*; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D011618:Psychotic Disorders / Q000097:blood / Q000150:complications; D006435:Renal Dialysis
D007980:Levodopa; D008734:Methoxyhydroxyphenylglycol; D006719:Homovanillic Acid